GLP-1 drugs and fertility: what the evidence actually supports

What's this video probably claiming?

Based on the caption "Fertilidad en la era de los GLP1" and the cited 2019 Jensterle et al. review in Human Reproduction Update, Dr. Gonzalez is likely arguing that GLP-1 receptor agonists improve fertility outcomes, particularly in women with obesity-related hormonal disruption, PCOS, or insulin resistance. The cited source is legitimate and does discuss GLP-1's physiological role in reproductive function, so this isn't a fringe take. He probably covers how weight loss induced by these drugs can restore ovulatory cycles, improve androgen profiles, and may affect implantation biology. There's also a good chance he's touching on the accidental pregnancy reports that surfaced after Ozempic went mainstream, which became its own social media moment. The partial citation to Cena et al. (Nappi RE as co-author, likely the 2020 paper in Obesity Reviews on obesity and female reproductive function) suggests he's building a multi-source argument rather than cherry-picking one paper. That's more rigorous than most health TikToks.

What does the science actually show?

The mechanistic case for GLP-1 affecting reproduction is real. GLP-1 receptors are expressed in the hypothalamus, pituitary, and ovarian tissue, which means these drugs aren't just gut hormones. Jensterle et al. (2019, Human Reproduction Update) documented GLP-1's role in modulating gonadotropin secretion and its downstream effects on ovarian function. In women with PCOS, liraglutide at 1.2-1.8 mg/day improved menstrual regularity and reduced testosterone levels in small RCTs. A 2022 study by Scorletti et al. showed that weight loss of 5-10% of body weight, achievable with semaglutide, can restore spontaneous ovulation in anovulatory women with obesity. The problem is that most fertility-specific trials are small, short, and not powered to detect pregnancy outcomes. The data on whether GLP-1 drugs improve live birth rates specifically is essentially nonexistent. What we have is: better metabolic environment, better hormone profiles, plausible mechanism. What we don't have: a randomized controlled trial showing these drugs make you more likely to take home a baby.

Where does the social media noise diverge from clinical reality?

Here's where things get messy. The "Ozempic babies" narrative that exploded on social media conflated two separate phenomena: restored fertility from weight loss versus some direct pro-fertility drug effect. Most clinicians think it's the former. When women who previously had anovulatory cycles start losing weight rapidly, their cycles return, and if they were relying on hormonal contraceptives that may have been less effective due to GI side effects from GLP-1 drugs (vomiting, delayed gastric emptying reducing pill absorption), unintended pregnancies follow. That's not the drug boosting fertility in a clinically meaningful way. It's a drug interaction and contraception failure issue that got rebranded as a fertility miracle. More importantly, semaglutide and tirzepatide are currently Category X-equivalent, meaning they are contraindicated in pregnancy. Novo Nordisk's own prescribing information recommends discontinuing semaglutide at least two months before a planned pregnancy. Any video that presents GLP-1 drugs as a fertility treatment without prominently addressing this point is leaving out the most clinically consequential part of the story.

What should you actually know?

If you have obesity-related anovulation or PCOS and your doctor is discussing GLP-1 options, the fertility conversation has legitimate scientific grounding. Weight loss through any mechanism, including GLP-1 drugs, can meaningfully improve hormonal function. That part is supported. What is not supported is using these drugs while actively trying to conceive. Current guidance from major reproductive endocrinology societies recommends stopping GLP-1 medications before attempting pregnancy and using reliable non-oral contraception while on them if pregnancy is not desired, specifically to account for absorption issues with oral pills. The research base is also heavily skewed toward women. Male fertility data on GLP-1 drugs is thin. One small study suggested improved sperm parameters with weight loss, but nothing isolates GLP-1 as the driver. Bottom line: GLP-1 drugs may improve the metabolic conditions that support fertility, but they are not fertility treatments, and they should not be taken during pregnancy. Any framing that blurs those lines is doing patients a disservice.